X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://endpts.com/seagens-former-commercial-chief-joins-the-board-at-healthcare-agency-minds-assembly/
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-overall-survival-phase-3-trial
https://www.onclive.com/view/brentuximab-vedotin-plus-avd-gets-positive-chmp-opinion-for-cd30-stage-iii-hodgkin-lymphoma
https://www.onclive.com/view/brecadd-proves-noninferior-to-ebeacopp-in-advanced-classical-hodgkin-lymphoma
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-advisers-back-xbb-targeted-covid-shots-2023-24-campaign-2023-06-15/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388
https://endpts.com/seagen-touts-phii-data-for-adcetris-opdivo-combo-a-alpha-partners-with-gilead-on-hiv/
https://www.biospace.com/article/seagen-eyes-a-key-frontline-indication-for-adcetris/
https://www.biospace.com/article/seagen-caps-off-big-week-with-pediatric-hodgkin-lymphoma-approval/
https://investor.seagen.com/press-releases/news-details/2022/Seagen-Announces-U.S.-FDA-Approval-of-New-Indication-for-ADCETRIS-brentuximab-vedotin-for-Children-with-Previously-Untreated-High-Risk-Hodgkin-Lymphoma/default.aspx
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388
https://www.fiercepharma.com/special-report/top-10-antibody-drug-conjugate-contenders-2021
https://www.businesswire.com/news/home/20201029006128/en/Seagen-Reports-Third-Quarter-2020-Financial-Results#:~:text=Revenues%3A%20Total%20revenues%20for%20the,the%20same%20periods%20in%202019.
https://www.fiercepharma.com/marketing/merck-s-seattle-genetics-adc-deal-extends-blockbuster-keytruda-franchise-analyst
http://www.pharmatimes.com/news/nice_backing_for_takedas_adcetris_for_rare_lymphoma_1344661
https://pharmafield.co.uk/pharma_news/nice-recommends-adcetris%E2%96%BC-brentuximab-vedotin-in-combination-with-chemotherapy-as-frontline-treatment-for-a-rare-type-of-lymphoma/
https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data
https://www.prnewswire.com/news-releases/eha25virtual-a-new-paradigm-in-relapsed-refractory-hodgkin-lymphoma-301074447.html
https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/
https://www.takeda.com/newsroom/newsreleases/2020/takeda-china-announces-adcetris-brentuximab-vedotin-is-approved-for-the-treatment-of-adult-patients-with-cd30-positive-lymphomas/
http://www.pharmatimes.com/news/keytruda_improves_pfs_in_classical_hodgkin_lymphoma_1327773
https://www.fiercepharma.com/pharma/merck-s-keytruda-builds-blood-cancer-case-head-win-against-seagen-s-adcetris
https://www.businesswire.com/news/home/20200302005320/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Significantly-Improved-Progression-Free-Survival/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.fiercepharma.com/pharma/as-adcetris-growth-slows-seattle-genetics-touts-strong-padcev-bladder-cancer-early-launch
https://www.businesswire.com/news/home/20191209005142/en/Seattle-Genetics-Takeda-Announce-Additional-Analyses-ADCETRIS%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.businesswire.com/news/home/20191125005237/en/Seattle-Genetics-Announces-Health-Canada-Approval-ADCETRIS%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388
https://www.biopharmadive.com/news/seattle-genetics-esmo-data-enfortumab-vedotin-bladder-cancer/563995/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-21-2019-1566366765.pdf
https://www.biospace.com/article/seattle-genetics-announces-pricing-of-public-offering-of-common-stock-at-70-00-per-share/
https://www.thepharmaletter.com/article/takeda-using-every-possible-channel-to-deliver-on-adcetris-potential-says-thanos-zomas
https://www.fiercepharma.com/pharma/seattle-genetics-investors-breathe-a-sigh-relief-as-adcetris-scores-30-sales-growth
Market Place
Share 
